Patents by Inventor Akbar Nayeem
Akbar Nayeem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12091462Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: GrantFiled: July 10, 2019Date of Patent: September 17, 2024Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
-
Publication number: 20240239909Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: February 14, 2024Publication date: July 18, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20240228664Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.Type: ApplicationFiled: July 21, 2023Publication date: July 11, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
-
Publication number: 20240132622Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.Type: ApplicationFiled: July 20, 2023Publication date: April 25, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
-
Publication number: 20240124597Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: August 22, 2023Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Patent number: 11926673Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 19, 2022Date of Patent: March 12, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11795231Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: February 11, 2022Date of Patent: October 24, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11773178Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 31, 2022Date of Patent: October 3, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Publication number: 20220169742Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: February 11, 2022Publication date: June 2, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, Jr., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220153856Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220144962Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: January 19, 2022Publication date: May 12, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20220073617Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: July 10, 2019Publication date: March 10, 2022Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
-
Patent number: 11261258Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: November 18, 2019Date of Patent: March 1, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11254750Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: October 26, 2020Date of Patent: February 22, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Publication number: 20210054090Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: October 26, 2020Publication date: February 25, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20200157233Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: November 18, 2019Publication date: May 21, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20180265851Abstract: Transglutaminase variants capable of conjugating an antibody that is not conjugated by wild-type transglutaminase from Streptomyces mobaraensis.Type: ApplicationFiled: September 30, 2016Publication date: September 20, 2018Inventors: Chetana RAO-NAIK, Ganapathy N. SARMA, Akbar NAYEEM
-
Patent number: 8420365Abstract: The invention provides gene-targeted non-human animals comprising a genetically modified 11?HSD1 gene encodes a mutant 11?HSD1 polypeptide which is modulated by human 11?HSD1 modulating compounds. The invention further provides cells expressing mutant 11?HSD1 and cells isolated from gene-targeted animals, which cells produce a mutant 11?HSD1. The invention further provides methods of identifying agents that modulate 11?HSD1 activity, and are useful to treat 11?HSD1-related metabolic disorders.Type: GrantFiled: October 8, 2008Date of Patent: April 16, 2013Assignee: Bristol-Myers Squibb CompanyInventors: David Gordon, Yuval Blat, Akbar Nayeem, Mark S. Kirby, Bin He
-
Publication number: 20110077395Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.Type: ApplicationFiled: December 2, 2010Publication date: March 31, 2011Inventors: James J. Li, Lawrence G. Hamann, Zheming Ruan, Christopher B. Cooper, Shung C. Wu, Ligaya M. Simpkins, Haixia Wang, Akbar Nayeem, Stanley R. Krystek
-
Publication number: 20100209990Abstract: The invention provides gene-targeted non-human animals comprising a genetically modified 11?HSD1 gene encodes a mutant 11?HSD1 polypeptide which is modulated by human 11?HSD1 modulating compounds. The invention further provides cells expressing mutant 11?HSD1 and cells isolated from gene-targeted animals, which cells produce a mutant 11?HSD1. The invention further provides methods of identifying agents that modulate 11?HSD1 activity, and are useful to treat 11?HSD1-related metabolic disorders.Type: ApplicationFiled: October 8, 2008Publication date: August 19, 2010Inventors: David Gordon, Yuval Blat, Akbar Nayeem, Mark S. Kirby, Bin He
